News for Travere Therapeutics, Inc. (TVTX)

Summary Travere Therapeutics Inc (TVTX) announced on April 10, 2025, that its Compensation Committee has granted inducement equity awards to six new employees.

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on April 10, 2025, the Compensation Committee of its Board of Directors granted inducement equit

Scotiabank analyst Greg Harrison has adjusted the price target for Travere Therapeutics (TVTX), lowering it to $30 from the previous $32. Despite this revision,

We recently published a list of 10 Best Small-Cap Stocks to Buy Before They Explode.  In this article, we are going to take a look at where Travere Therapeutics, Inc.

Summary Travere Therapeutics Inc (TVTX) announced on March 17, 2025, the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Admi

sNDA submission based on results from Phase 3 DUPLEX and Phase 2 DUET studies of FILSPARI in FSGS If approved, FILSPARI could become the first and only FDA-app

**media[568233]**

SAN DIEGO, March 12, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on March 10, 2025, the Compensation Committee of

**media[564921]**

Travere Therapeutics' Filspari boosts revenue with FDA approval, but heavy losses and competitive threats raise concerns for 2025. Click to read why TVTX is a Hold.

**media[555747]**

**media[552829]**

**media[552077]**

Summary Travere Therapeutics Inc (TVTX), a biopharmaceutical company dedicated to developing therapies for rare diseases, announced on February 24, 2025, that i

SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. ( TVTX) today announced that company management will participate in the following upco

We recently published a list of the 10 Best Performing Pharma Stocks So Far in 2025. In this article, we are going to take a look at where Travere Therapeutics, Inc.

On February 20, Jared Holz, Mizuho healthcare sector strategist, appeared on 'Squawk Box' to discuss the potential challenges and opportunities the pharmaceutical industry may face under the new Trump...

Travere Therapeutics Inc (TVTX) has released its financial results for the fourth quarter and full year of 2024, alongside a corporate update. The company repor

Travere Therapeutics, Inc. (NASDAQ:TVTX) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ETCompany ParticipantsVictoria Prescott - Manager of...